Facebook
Twitter
LinkedIn
ForwardMiami Cancer Institute Multispecialty Grand Rounds – Advances in Radiation Therapy and Systemic Therapy for Hepatocellular Carcinoma (HCC)
Systemic therapy for hepatocellular carcinoma (HCC) has changed markedly since the introduction of the molecular targeted agent sorafenib. Dr. Theodore Hong will review the history and development of radiation therapy in HCC and discuss the outcomes when implementing stereotactic body radiation therapy.
Target Audience
Oncologists, Radiation Oncologists, Hematology Oncologists, Radiation Therapists, General Surgeons, General Practitioners, Obstetricians and Gynecologists, Nurses, Pharmacists, Respiratory Therapists, Patient Navigators and all other interested healthcare professionals.
Learning Objectives
- Analyze the history and development of radiation therapy in HCC.
- Assess the role of protons in HCC.
- Identify and assess the rise of inter-operative based therapies in advanced HCC.
Theodore Hong, M.D.
Professor, Radiation Oncology, Harvard Medical School
Director, Gastrointestinal Service, Radiation Oncology, Massachusetts General Hospital
Associate Clinical Director, Radiation Oncology, Massachusetts General Hospital
Boston, Massachusetts
Theodore Hong, M.D., faculty of this educational activity, has received research support from Taiho, Astra-Zenecz, BMS, GSK, IntraOp and Ipsen, he is a consultant with Synthetic Biologics, Novocure, Boston Scientific, Inivata and Merck. He is an advisor with PanTher Therapeutics (Equity) Lustgarten and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.
Guilherme Rabinowits, M.D., conference series director, has indicated that he is a consultant with Sanofi and Regeneron. All of the relevant financial relationships listed for this individual have been mitigated.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationship(s) to disclose with ineligible companies*
*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been approved for 1 credit hour, CE Broker Course #20-680158, by the Florida Boards of Medicine, Osteopathic Medicine and by the Florida Council of Physician Assistants.
This activity has also been approved for 1 credit hour for Nurse Practitioners, Nurses, Pharmacists and Techs and Respiratory Therapists. Baptist Health South Florida CE Broker Provider #50-182.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 General certificate of attendance
- 1.00 Nurse Practitioners
- 1.00 Florida Board of Nursing
- 1.00 Florida Board of Pharmacy
- 1.00 Florida Board of Respiratory Therapy
Required Hardware/Software
 | PC/Mac UsersThis site is supported on the most recent stable releases of the following browsers:
| ||||||
 | Mobile UsersThis site is supported on the following mobile devices:
| ||||||
 | Technical SupportIf you are experiencing technical difficulties or have received an error message, please send an email to [email protected] and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours. |
